1. Inicio
  2. Publicaciones
  3. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

Fecha de publicación:

Autores de INCLIVA

Participantes ajenos a INCLIVA

  • Ortiz, A
  • Vergara, A
  • Jacobs-Cacha, C
  • Martinez-Castelao, A
  • Soler, MJ

Grupos y Plataformas de I+D+i

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin-angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m(2). Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin-angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD. We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication.

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Datos de la publicación

ISSN/ISSNe:
0931-0509, 1460-2385

NEPHROLOGY DIALYSIS TRANSPLANTATION  OXFORD UNIV PRESS

Tipo:
Review
Páginas:
13-23
PubMed:
32003834

Citas Recibidas en Web of Science: 23

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • chronic renal failure; diabetic kidney disease; ESRD; SGLT2 inhibitors; type 2 diabetes

Financiación

INSTITUTO SALUD CARLOS III (CB16/11/00420)

Proyectos y Estudios Clínicos

INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER

Investigador Principal: JUAN SANCHIS FORES

CB16/11/00420 . INSTITUTO SALUD CARLOS III

Cita

Compartir